Treatment News : A Likely Uptick in PrEP Users as Studies Seek New Answers

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » February 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


February 3, 2014

A Likely Uptick in PrEP Users as Studies Seek New Answers

Despite the famously slow uptake of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition among HIV-negative people, the rate of new prescriptions appears to have accelerated, according to an essay in The Lancet. Meanwhile, numerous clinical trials are currently seeking to address the myriad questions and concerns surrounding the controversial application of this antiretroviral.

As has been widely reported, just 1,774 people used Truvada as PrEP between January 2011 and March 2013. Among them, 48 percent were women. However, the Lancet points out, there is reason to believe that the rate of new prescriptions is increasing, given the fact that 350 were issued during the first quarter of 2013. Also, the article theorizes that many of those who are currently enrolled in the various clinical trials researching Truvada as PrEP will eventually seek prescriptions for the drug once the studies complete.

While the crop of research studies currently examining PrEP is addressing ongoing concerns about toxicity and non-adherence, two current studies are also exploring whether Truvada may be effective at less-than-daily dosing. And a United Kingdom trial known as the PROUD study pilot is also looking at whether men who have sex with men (MSM) on PrEP engage in “risk compensation”—having riskier sex, or increasing the number of sexual partners because of a perceived reduction in risk—and shifting1 from a low- to a high-risk category.

To read the Lancet article, click here.

Search: Truvada, PrEP, pre-exposure prophylaxis, tenofovir, emtricitabine, The Lancet, slow uptake, risk compensation, PROUD, MSM.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.